0001209191-18-045509.txt : 20180806 0001209191-18-045509.hdr.sgml : 20180806 20180806160838 ACCESSION NUMBER: 0001209191-18-045509 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180802 FILED AS OF DATE: 20180806 DATE AS OF CHANGE: 20180806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Davidson David CENTRAL INDEX KEY: 0001578696 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35966 FILM NUMBER: 18994801 MAIL ADDRESS: STREET 1: C/O BLUEBIRD BIO, INC. STREET 2: 840 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: bluebird bio, Inc. CENTRAL INDEX KEY: 0001293971 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 339-499-9300 MAIL ADDRESS: STREET 1: 60 BINNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Genetix Pharmaceuticals Inc DATE OF NAME CHANGE: 20040616 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-08-02 0 0001293971 bluebird bio, Inc. BLUE 0001578696 Davidson David C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer Common Stock 2018-08-02 4 M 0 7000 5.5004 A 31905 D Common Stock 2018-08-02 4 S 0 5790 150.1773 D 26115 D Common Stock 2018-08-02 4 S 0 1110 151.2149 D 25005 D Common Stock 2018-08-02 4 S 0 100 152.10 D 24905 D Stock Option (right to buy) 5.5004 2018-08-02 4 M 0 7000 0.00 D 2023-01-16 Common Stock 7000 43951 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2017. The range in prices for the transaction reported on this line was $150.00 to $150.90. The average weighted price was $150.1773. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The range in prices for the transaction reported on this line was $151.00 to $151.60. The average weighted price was $151.2149. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, with the remainder of the shares vesting in equal monthly installments over the following three years. /s/ Jason F. Cole, Attorney-in-Fact 2018-08-06